Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 74 results for cystic fibrosis

  1. Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]

    In development Reference number: GID-TA11564 Expected publication date:  08 July 2026

    Technology appraisal guidance
    In development

  2. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)

    NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .

    Medtech innovation briefing
    Published
    10 July 2020

  3. Osteoporosis: assessing the risk of fragility fracture (CG146)

    This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.

    Clinical guideline
    Last updated
    7 February 2017
    View recommendations

    Sections for CG146

  4. Data collection agreement

    can make Modular updates This agreement relates to treating cystic fibrosis patients with: Ivacaftor, tezacaftor and elexacaftor...

  5. Monitoring for cystic-fibrosis-related diabetes:- What is the most effective strategy to detect diabetes in people with cystic fibrosis?

    Monitoring for cystic-fibrosis-related diabetes:- What is the most effective strategy to detect diabetes in people with cystic...

    Research recommendation
    Published
    18 October 2018

  6. Ex-situ machine perfusion devices for extracorporeal preservation of lungs for transplant

    In development Reference number: GID-HTE10084 Expected publication date: TBC

    Health technology evaluations
    In development

  7. Mucoactive agents:- What is the most clinically and cost-effective dose of rhDNase (dornase alfa; recombinant human deoxyribonuclease) for people with cystic fibrosis?

    for people with cystic fibrosis? Any explanatory notes(if applicable) Why this is important- People with cystic fibrosis...

    Research recommendation
    Published
    18 October 2018

  8. Airway clearance techniques:- How effective are daily airway clearance techniques in maintaining lung function in infants and children with cystic fibrosis?

    techniques in maintaining lung function in infants and children with cystic fibrosis? Any explanatory notes(if applicable) Why this is...

    Research recommendation
    Published
    6 November 2018

  9. Psychological assessment:- What is the most effective measure of psychological functioning to use as a test for thresholds of concern in people with cystic fibrosis?

    functioning to use as a test for thresholds of concern in people with cystic fibrosis? Any explanatory notes(if applicable) Why this is...

    Research recommendation
    Published
    18 October 2018

  10. Smart One for measuring lung function (MIB96)

    NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .

    Medtech innovation briefing
    Published
    9 February 2017

  11. Monitoring pulmonary disease:- Is lung clearance index a useful and cost-effective tool for the routine assessment and monitoring of changes in pulmonary status in people with cystic fibrosis?

    assessment and monitoring of changes in pulmonary status in people with cystic fibrosis? Any explanatory notes(if applicable) Why this...

    Research recommendation
    Published
    6 November 2018

  12. Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

    In development Reference number: GID-TA11793 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  13. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598]

    In development Reference number: GID-HST10067 Expected publication date:  19 August 2026

    Highly specialised technologies guidance
    In development

  14. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  15. Living-donor lung transplantation for end-stage lung disease (HTG111)

    Evidence-based recommendations on living-donor lung transplantation for end-stage lung disease. This involves removing a lung from each of the two donors and replacing the recipient's lungs with the donor lungs.

    HealthTech guidance
    Published
    24 May 2006
    View recommendations

    Sections for HTG111